AMO&#x27;s IOL to be reimbursed in US

Study: MERCURY-3 trial results support efficacy of Roclanda

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

Study: MERCURY-3 trial results support efficacy of Roclanda

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Intravitreal cell therapy as protection from degenerations

September 18th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

Study: MERCURY-3 trial results support efficacy of Roclanda

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

Study: Children with vision impairment have reduced quality of life

Related Content

A child wearing glasses sits in a classroom among her peers who do not have glasses. Image credit: ©Drazen – stock.adobe.com

September 20th 2023

Intravitreal cell therapy as protection from degenerations

Research from Orbis International analyses the overall wellbeing of children with common childhood vision problems

A cell, as imaged under a microscope. Image credit: ©vipman4 – stock.adobe.com

September 18th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

Stem cells may replace some lost retinal neurons

A digital illustration of an eye with charts and numbers imposed atop it. Image credit: ©ArticMinimal – stock.adobe.com

Study: MERCURY-3 trial results support efficacy of Roclanda

The AI retinal scanning model will be free to use for all institutions

A group of doctors and scientists walk through a laboratory. Image credit: ©Oostendorp/peopleimages.com – stock.adobe.com

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

A series of test tubes in a laboratory. Image credit: ©Vladislava – stock.adobe.com

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

A patient administers eye drops to his own eye. Image credit: ©Krakenimages.com – stock.adobe.com